Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-9688 in Patients with Chronic Hepatitis B

Trial Profile

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-9688 in Patients with Chronic Hepatitis B

Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Nov 2018

At a glance

  • Drugs GS 9688 (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 13 Nov 2018 Results presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases
    • 11 Oct 2018 According to a Gilead Sciences media release, data from this trial will be presented at The Liver Meeting 2018 (Nov 2018).
    • 09 Jul 2018 Planned number of patients changed from 40 to 60.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top